Themis Medicare Limited

NSEI:THEMISMED Stock Report

Market Cap: ₹27.2b

Themis Medicare Valuation

Is THEMISMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of THEMISMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: THEMISMED (₹295) is trading above our estimate of fair value (₹155.37)

Significantly Below Fair Value: THEMISMED is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THEMISMED?

Key metric: As THEMISMED is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for THEMISMED. This is calculated by dividing THEMISMED's market cap by their current earnings.
What is THEMISMED's PE Ratio?
PE Ratio51.3x
Earnings₹529.90m
Market Cap₹27.16b

Price to Earnings Ratio vs Peers

How does THEMISMED's PE Ratio compare to its peers?

The above table shows the PE ratio for THEMISMED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.7x
INDOCO Indoco Remedies
92.6x72.2%₹29.7b
507747 TTK Healthcare
26.5xn/a₹21.2b
590006 Amrutanjan Health Care
42.7xn/a₹20.3b
500672 Novartis India
29xn/a₹25.4b
THEMISMED Themis Medicare
51.3xn/a₹27.2b

Price-To-Earnings vs Peers: THEMISMED is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the peer average (47.7x).

Price to Earnings Ratio vs Industry

How does THEMISMED's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$69.15m
524652 Ind-Swift
2xn/aUS$12.99m
No more companies available in this PE range
THEMISMED 51.3xIndustry Avg. 31.7xNo. of Companies17PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: THEMISMED is expensive based on its Price-To-Earnings Ratio (51.3x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is THEMISMED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THEMISMED PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate THEMISMED's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹294.55

7D

-0.4%

1Y

-21.5%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Granules India

₹135.5b

Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly.

532482

₹574.50

7D

8.6%

1Y

48.3%